Compumedics has reported that its new Somte PSG portable sleep-testing systems were chosen as part of a major new study to further investigate the link between sleep disorders and cardio-vascular disease in various ethnic and racial populations.

Compumedics said the Somte PSG System incorporates advanced technology to record sleep studies in either the home or the sleep-lab settings and the contract is worth approximately $300 thousand adding to the company’s success in supplying NIH-funded studies.

Somte PSG was chosen because of its ability to record complex sleep studies in the home environment with acceptable participant burden, according to Susan Redline, professor of Medicine at Harvard Medical School and the senior investigator for the Multi-Ethnic Study of Atherosclerosis (MESA) Sleep Study.

Compumedics chairman and CEO David Burton said the Somte PSG systems deliver data recording with integrated waveform displays, but at the same time incorporate the user friendliness and trouble-free patient operation essential for reliable home sleep testing.

"The factors will enable professor Redline’s team to collect high quality and meaningful data from these patients with a minimum of inconvenience. In addition, this project comes at an opportune time for Compumedics when the company is focusing its growth on its core product lines, including Somte PSG, with the expansion of its global sales force," Burton said.

Reportedly, the MESA was established by the NIH in 2000 with the aim of identifying ethnic and racial differences in risk factors and subclinical and clinical cardiovascular disease and the new MESA Sleep Study has been funded to further understand those risks.